A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial)
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms MOCHA
- 28 Nov 2022 Status changed from recruiting to discontinued.
- 20 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Dec 2021.
- 25 Sep 2019 Planned End Date changed from 1 Aug 2022 to 1 Sep 2022.